TG Therapeutics (TGTX) Reports Q3 Loss of $0.43
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
TG Therapeutics (TGTX) Reports Open Enrollment for Phase I Study of Novel BTK Inhibitor, TG-1701
November 13, 2018 7:36 AM ESTTG Therapeutics, Inc. (NASDAQ: TGTX) today announced the first Company sponsored Phase I study of its novel, orally available and covalently-bound Bruton Tyrosine Kinase (BTK) inhibitor, TG-1701, is open for enrollment for patients with relapsed or refractory B-cell malignancies. The first cohort evaluating TG-1701 at a dose of 100 mg once-daily has been fully enrolled, and the first patient enrolled, a patient with relapsed/refractory Mantle Cell Lymphoma (MCL), achieved a partial response (PR) at the first efficacy assessment. The remaining two... More
